Compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-10954244-B2
Application number	US-201916422606-A
Country	US
Kind code	B2
Filing date	May 24, 2019
Priority date	May 30, 2013
Publication date	Mar 23, 2021
Grant date	Mar 23, 2021

Abstract

The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

First claim

What is claimed is:

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

2. A method of treating an ocular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

3. A method of inhibiting signaling of a growth factor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

4. The method of claim 3 , wherein the growth factor is a vascular endothelial growth factor.

5. A method of treating a disease associated with abnormal angiogenesis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .

6. A pharmaceutical composition, comprising the compound of claim 1 and a pharmaceutically acceptable excipient.

7. A method of treating an ocular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 6 .

8. A method of inhibiting signaling of a growth factor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 6 .

9. The method of claim 3 , wherein the growth factor is a vascular endothelial growth factor.

10. A method of treating a disease associated with abnormal angiogenesis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 6 .

11. A composition, comprising the compound of claim 1 .

12. A method of treating an ocular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of claim 11 .

13. A method of inhibiting signaling of a growth factor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of claim 11 .

14. The method of claim 13 , wherein the growth factor is a vascular endothelial growth factor.

15. A method of treating a disease associated with abnormal angiogenesis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the composition of claim 11 .

16. A pharmaceutical composition, comprising the compound of claim 1 and a pharmaceutically acceptable excipient,
wherein the pharmaceutical composition is formulated for enteral, parenteral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical, mucosal, nasal, bucal, sublingual, intratracheal, or bronchial administration.

17. A method of treating an ocular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 16 .

18. A method of inhibiting signaling of a growth factor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 16 .

19. The method of claim 18 , wherein the growth factor is a vascular endothelial growth factor.

20. A method of treating a disease associated with abnormal angiogenesis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 16 .

Assignees

• Kala Pharmaceuticals Inc

Inventors

• Ong Winston Zapanta
• Nowak Pawel Wojciech
• Askew Ben C
• Good Andrew

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P7/10

  Antioedematous agents; Diuretics · CPC title